Thiopental sodium loaded solid lipid nano-particles attenuates obesity-induced cardiac dysfunction and cardiac hypertrophy via inactivation of inflammatory pathway

References

• Abel ED, Doenst T. (2011). Mitochondrial adaptations to physiological vs. pathological cardiac hypertrophy. Cardiovasc Res 90:234–42.
   PubMed Web of Science ®Google Scholar
• Arozal W, Sari FR, Watanabe K, et al. (2011). Carvedilol-afforded protection against daunorubicin-induced cardiomyopathic rats in vivo: effects on cardiac fibrosis and hypertrophy. ISRN Pharmacol 2011:430549–8.
   PubMedGoogle Scholar
• Berg AH, Scherer PE. (2005). Adipose tissue, inflammation, and cardiovascular disease. Circ Res 96:939–49.
   PubMed Web of Science ®Google Scholar
• Black PH, Garbutt LD. (2002). Stress, inflammation and cardiovascular disease. J Psychosom Res 52:1–23.
   PubMed Web of Science ®Google Scholar
• Black S, Kushner I, Samols D. (2004). C-reactive protein. J Biol Chem 279:48487–90.
   PubMed Web of Science ®Google Scholar
• D’Agostino RB, Vasan RS, Pencina MJ, et al. (2008). General cardiovascular risk profile for use in primary care: the Framingham heart study. Circulation 117:743–53.
   PubMed Web of Science ®Google Scholar
• Dai DF, Johnson SC, Villarin JJ, et al. (2011). Mitochondrial oxidative stress mediates angiotensin II-induced cardiac hypertrophy and Galphaq overexpression-induced heart failure . Circ Res 108:837–46.
   PubMed Web of Science ®Google Scholar
• Dogan Z, Yuzbasioglu MF, Kurutas EB, et al. (2010). Thiopental improves renal ischemia-reperfusion injury. Ren Fail 32:391–5.
   PubMed Web of Science ®Google Scholar
• Du J, He W, Zhang C, et al. (2020). Pentamethylquercetin attenuates cardiac remodeling via activation of the sestrins/Keap1/Nrf2 pathway in MSG-induced obese mice. Biomed Res Int 2020:3243906.
   PubMed Web of Science ®Google Scholar
• Ebert TJ, Kanitz DD, Kampine JP. (1990). Inhibition of sympathetic neural outflow during thiopental anesthesia in humans. Anesth Analg 74:319–26.
   Google Scholar
• Ekambaram P, Abdul Hasan Sathali A. (2011). Formulation and evaluation of solid lipid nanoparticles of ramipril. J Young Pharm 3:216–20.
   PubMedGoogle Scholar
• Ferrucci L, Fabbri E. (2018). Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty. Nat Rev Cardiol 15:505–22.
   PubMed Web of Science ®Google Scholar
• Fisk M, Gajendragadkar PR, Mäki-Petäjä KM, et al. (2014). Therapeutic potential of p38 MAP kinase inhibition in the management of cardiovascular disease. Am J Cardiovasc Drugs 14:155–65.
   PubMed Web of Science ®Google Scholar
• Geng Z, Fan WY, Zhou B, et al. (2019). FNDC5 attenuates obesity-induced cardiac hypertrophy by inactivating JAK2/STAT3-associated inflammation and oxidative stress. J Transl Med 17.
   PubMed Web of Science ®Google Scholar
• Graves JD, Draves KE, Craxton A, et al. (1996). Involvement of stress-activated protein kinase and p38 mitogen-activated protein kinase in mIgM-induced apoptosis of human B lymphocytes. Proc Natl Acad Sci USA 93:13814–8.
   PubMed Web of Science ®Google Scholar
• Kaptoge S, Di Angelantonio E, Pennells L, et al. (2012). C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med 367:1310–20.
   PubMed Web of Science ®Google Scholar
• Kim EK, Choi EJ. (2010). Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta 1802:396–405.
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Takeda Y, Taninishi H, et al. (2007). Quantitative evaluation of the neuroprotective effects of thiopental sodium, propofol, and halothane on brain ischemia in the gerbil: Effects of the anesthetics on ischemic depolarization and extracellular glutamate concentration. J Neurosurg Anesthesiol 19:171–8.
   PubMed Web of Science ®Google Scholar
• Lang H, Xiang Y, Ai Z, et al. (2018). UCP3 ablation exacerbates high-salt induced cardiac hypertrophy and cardiac dysfunction. Cell Physiol Biochem 46:1683–92.
   PubMedGoogle Scholar
• Lyon RC, Zanella F, Omens JH, Sheikh F. (2015). Mechanotransduction in cardiac hypertrophy and failure. Circ Res 116:1462–76.
   PubMed Web of Science ®Google Scholar
• Madamanchi NR, Vendrov A, Runge MS. (2005). Oxidative stress and vascular disease. Arterioscler Thromb Vasc Biol 25:29–38.
   PubMed Web of Science ®Google Scholar
• Mooney T. (2012). Cardiovascular disease. In Nursing standard (Royal College of Nursing (Great Britain): 1987). 59.
   Google Scholar
• Muslin AJ. (2008). MAPK signalling in cardiovascular health and disease: molecular mechanisms and therapeutic targets. Clin Sci 115:203–18.
   PubMed Web of Science ®Google Scholar
• Nayak AP, Tiyaboonchai W, Patankar S, et al. (2010). Curcuminoids-loaded lipid nanoparticles: Novel approach towards malaria treatment. Colloids Surf B Biointerfaces 81:263–73.
   PubMed Web of Science ®Google Scholar
• Nishina K, Akamatsu H, Mikawa K, et al. (1998). The inhibitory effects of thiopental, midazolam, and ketamine on human neutrophil functions. Anesth Analg 86:159–65.
   PubMed Web of Science ®Google Scholar
• Poledne R, Králová Lesná I. (2018). Inflammation and atherosclerosis. Vnitr Lek 64:1142–6.
   Google Scholar
• Rahman M, Al-Ghamdi SA, Alharbi KS, et al. (2019). Ganoderic acid loaded nano-lipidic carriers improvise treatment of hepatocellular carcinoma. Drug Deliv 26:782–93.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Silvertown JD. (2008). Inflammation, C-reactive protein, and atherothrombosis. J Periodontol 79:1544–51.
   PubMed Web of Science ®Google Scholar
• Rosca MG, Tandler B, Hoppel CL. (2013). Mitochondria in cardiac hypertrophy and heart failure. J Mol Cell Cardiol 55:31–41.
   PubMed Web of Science ®Google Scholar
• Schultz MG, La Gerche A, Sharman JE. (2017). Blood pressure response to exercise and cardiovascular disease. Curr Hypertens Rep 19.
   Web of Science ®Google Scholar
• Shimizu I, Minamino T. (2016). Physiological and pathological cardiac hypertrophy. J Mol Cell Cardiol 97:245–62.
   PubMed Web of Science ®Google Scholar
• Shrivastava AK, Singh HV, Raizada A, Singh SK. (2015). C-reactive protein, inflammation and coronary heart disease. Egypt Hear J 67:89–97.
   Web of Science ®Google Scholar
• Silambarasan T, Manivannan J, Priya MK, et al. (2014). Sinapic acid prevents hypertension and cardiovascular remodeling in pharmacological model of nitric oxide inhibited rats. PLoS One 9:e115682.
   PubMed Web of Science ®Google Scholar
• Siti HN, Kamisah Y, Kamsiah J. (2015). The role of oxidative stress, antioxidants and vascular inflammation in cardiovascular disease (a review). Vascul Pharmacol 71:40–56.
   PubMed Web of Science ®Google Scholar
• Stef Á Nsson BV, Brunelli SM, Cabrera C, et al. (2014). Intradialytic hypotension and risk of cardiovascular disease. CJASN 9:2124–32.
   PubMed Web of Science ®Google Scholar
• Sumithran P, Proietto J. (2014). Peripheral endocrine response to weight loss. In: Metabolic medicine and surgery. 251–264.
   Google Scholar
• Üner M. (2006). Preparation, characterization and physico-chemical properties of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC): their benefits as colloidal drug carrier systems. Pharmazie 61:375–86.
   PubMed Web of Science ®Google Scholar
• Wang XY, Huang GY, Lian FZ, et al. (2019). Protective effect of Xin-Ji-Er-Kang on cardiovascular remodeling in high-salt induced hypertensive mice: role ofoxidative stress and endothelial dysfunction. Biomed Pharmacother 115.
   Web of Science ®Google Scholar
• Wu R, Yin D, Sadekova N, et al. (2012). Protective effects of aspirin from cardiac hypertrophy and oxidative stress in cardiomyopathic hamsters. Oxid Med Cell Longev 2012:761710.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Tang Q. (2016). GW27-e0437 Daidzein attenuates pressure overload-induced cardiac remodeling via inactivating mitochondrial pathway of apoptosis. J Am Coll Cardiol 68:C18.
   Web of Science ®Google Scholar